REGENXBIO Reports Phase II Data for Wet AMD Gene Therapy at AAO
Portfolio Pulse from Benzinga Newsdesk
REGENXBIO Inc. (NASDAQ:RGNX) reported positive Phase II data for its gene therapy ABBV-RGX-314 for wet AMD, showing significant reduction in treatment burden and sustained visual acuity. The therapy, developed with AbbVie, could become a one-time treatment option for bilateral wet AMD.
October 21, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
REGENXBIO's Phase II data for ABBV-RGX-314 shows potential as a one-time treatment for bilateral wet AMD, reducing treatment burden and maintaining vision. This positions RGNX as a leader in gene therapy for retinal diseases.
The positive Phase II data for ABBV-RGX-314 indicates a significant reduction in treatment burden for wet AMD patients, which could lead to increased adoption and market potential. This positions REGENXBIO as a leader in gene therapy for retinal diseases, likely boosting investor confidence and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100